AndroGel Medicaid Coverage by State Tier (2026 Guide)

What the labeling says about testosterone gel

AndroGel is a topical testosterone gel. FDA says testosterone products are approved only for men who lack or have low testosterone in conjunction with an associated medical condition, such as testicular failure or hypothalamus or pituitary problems. None of the approved products are approved for men with low testosterone who lack an associated medical condition [1].

The details below come from the generic testosterone gel 1.62% label (Padagis, effective August 2025), not from an AndroGel label [2]. That label says safety and efficacy in men with age-related hypogonadism have not been established. FDA said in June 2026 that it had requested removal of that limitation of use from testosterone labels [1]. The label also says testosterone is a Schedule III controlled substance under the Controlled Substances Act, and that before starting, hypogonadism should be confirmed with morning serum testosterone measured on at least two separate days, both below the normal range [2].

Why no state tier is listed

A formulary tier sets cost-sharing, and a plan may attach prior authorization or step therapy. These are plan decisions that can differ by state and by plan, and FDA labeling does not set them. The label requirement to confirm low morning testosterone on two days is a prescribing instruction, not a Medicaid tier or prior authorization rule [2].

Where to check your own coverage

Your plan's drug list, read with its prior authorization and step-therapy notes for AndroGel and for generic testosterone gel, is the document that governs your coverage. Whether AndroGel is covered, preferred or non-preferred in a given state depends on that plan.